[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLDsHMkqABvugcLBIiIwvCtHcwM3gN1JUxNgIy4a3mGQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":80,"rows":87},"Glaukos Corporation",[4],65,false,11,15,10691,17,33,[14,16,19,22,24,27,29,32],{"name":15,"count":8},"Glaucoma, Open-Angle",{"name":17,"count":18},"Glaucoma",9,{"name":20,"count":21},"Open-Angle Glaucoma",6,{"name":23,"count":21},"Open-angle Glaucoma",{"name":25,"count":26},"Keratoconus",5,{"name":28,"count":26},"Ocular Hypertension",{"name":30,"count":31},"Open Angle Glaucoma",4,{"name":33,"count":34},"Progressive Keratoconus",3,[36,41,46,51,56,61,66,71,76],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05314738","Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus","2025-08","NXL Energy 1",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05966493","A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED","2025-12","lufepirsen high dose",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","2026-06","Travoprost",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","2026-08","iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07400965","Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis","2026-09","GLK-321 low dose BID",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07400952","Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","2027-04","GLK-221 Ophthalmic Solution",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06066645","Travoprost Intraocular Implant + iStent Infinite","2027-05","Travoprost Intraocular Implant",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07075718","Phase 2\u002FPhase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","2028-03","Gen 2 Travoprost Intracameral Implant",{"nctId":77,"briefTitle":78,"date":79,"intervention":75},"NCT07495852","Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","2028-06",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,112,136,165,187,224,244,267,285,303,321,339,357,382,400,418,436,486,511,537,555,573,615,648,684,706,732,755,781,799,836,858,880,921,947,965,983,1001,1019,1037,1055,1073,1091,1109,1139,1157,1175,1193,1211,1229,1247],{"intervention":70,"totalTrials":89,"cells":90},1,{"EARLY_PHASE1":91,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":110},{"trials":92,"activeCount":93},[],0,{"trials":95,"activeCount":93},[],{"trials":97,"activeCount":93},[],{"trials":99,"activeCount":93},[],{"trials":101,"activeCount":89,"soonestReadout":69},[102],{"nctId":67,"briefTitle":68,"status":103,"phases":104,"primaryCompletion":69,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"RECRUITING",[85],"2028-02","2023-09-14",150,[15],[70],{"trials":111,"activeCount":93},[],{"intervention":55,"totalTrials":89,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":134},{"trials":115,"activeCount":93},[],{"trials":117,"activeCount":93},[],{"trials":119,"activeCount":93},[],{"trials":121,"activeCount":93},[],{"trials":123,"activeCount":89,"soonestReadout":54},[124],{"nctId":52,"briefTitle":53,"status":103,"phases":125,"primaryCompletion":54,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":133},[85],"2027-06","2025-01-13",132,[130,131,132],"Glaucoma, Open-angle","Ocular Hypertension (OHT)","Phacoemulsification Cataract Surgery",[55],{"trials":135,"activeCount":93},[],{"intervention":75,"totalTrials":137,"cells":138},2,{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":161,"NA":163},{"trials":140,"activeCount":93},[],{"trials":142,"activeCount":93},[],{"trials":144,"activeCount":93},[],{"trials":146,"activeCount":137,"soonestReadout":74},[147,155],{"nctId":77,"briefTitle":78,"status":103,"phases":148,"primaryCompletion":79,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":153},[84],"2032-03","2026-02-17",510,[17],[75,154],"Timolol eye drops 0.5%",{"nctId":72,"briefTitle":73,"status":103,"phases":156,"primaryCompletion":74,"completion":149,"start":157,"enrollment":158,"conditions":159,"interventions":160},[83,84],"2025-06-12",610,[17],[75,154],{"trials":162,"activeCount":93},[],{"trials":164,"activeCount":93},[],{"intervention":154,"totalTrials":137,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":183,"NA":185},{"trials":168,"activeCount":93},[],{"trials":170,"activeCount":93},[],{"trials":172,"activeCount":93},[],{"trials":174,"activeCount":137,"soonestReadout":74},[175,179],{"nctId":77,"briefTitle":78,"status":103,"phases":176,"primaryCompletion":79,"completion":149,"start":150,"enrollment":151,"conditions":177,"interventions":178},[84],[17],[75,154],{"nctId":72,"briefTitle":73,"status":103,"phases":180,"primaryCompletion":74,"completion":149,"start":157,"enrollment":158,"conditions":181,"interventions":182},[83,84],[17],[75,154],{"trials":184,"activeCount":93},[],{"trials":186,"activeCount":93},[],{"intervention":188,"totalTrials":137,"cells":189},"Vehicle",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":191,"activeCount":93},[],{"trials":193,"activeCount":93},[],{"trials":195,"activeCount":89,"soonestReadout":44},[196,210],{"nctId":197,"briefTitle":198,"status":199,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT04081103","NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries","TERMINATED",[83],"2022-02-07","2020-06-30",35,[205],"Corneal Persistent Epithelial Defect",[207,208,188,209],"Nexagon® (lufepirsen) High Dose Concentration","Nexagon® (lufepirsen) Low Dose Concentration","Open-label Nexagon®",{"nctId":42,"briefTitle":43,"status":103,"phases":211,"primaryCompletion":44,"completion":44,"start":212,"enrollment":213,"conditions":214,"interventions":216},[83],"2023-08-17",84,[215],"Persistent Corneal Epithelial Defect",[45,188,217],"lufepirsen low dose",{"trials":219,"activeCount":93},[],{"trials":221,"activeCount":93},[],{"trials":223,"activeCount":93},[],{"intervention":65,"totalTrials":89,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":227,"activeCount":93},[],{"trials":229,"activeCount":93},[],{"trials":231,"activeCount":89,"soonestReadout":64},[232],{"nctId":62,"briefTitle":63,"status":103,"phases":233,"primaryCompletion":64,"completion":64,"start":234,"enrollment":235,"conditions":236,"interventions":237},[83],"2025-12-23",100,[25],[65],{"trials":239,"activeCount":93},[],{"trials":241,"activeCount":93},[],{"trials":243,"activeCount":93},[],{"intervention":40,"totalTrials":89,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":261,"PHASE4":263,"NA":265},{"trials":247,"activeCount":93},[],{"trials":249,"activeCount":93},[],{"trials":251,"activeCount":89,"soonestReadout":39},[252],{"nctId":37,"briefTitle":38,"status":103,"phases":253,"primaryCompletion":39,"completion":254,"start":255,"enrollment":107,"conditions":256,"interventions":257},[82,83],"2026-02","2022-03-08",[33],[40,258,259,260],"NXL Energy 2","NXL Energy 3","Sham Treatment",{"trials":262,"activeCount":93},[],{"trials":264,"activeCount":93},[],{"trials":266,"activeCount":93},[],{"intervention":258,"totalTrials":89,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":270,"activeCount":93},[],{"trials":272,"activeCount":93},[],{"trials":274,"activeCount":89,"soonestReadout":39},[275],{"nctId":37,"briefTitle":38,"status":103,"phases":276,"primaryCompletion":39,"completion":254,"start":255,"enrollment":107,"conditions":277,"interventions":278},[82,83],[33],[40,258,259,260],{"trials":280,"activeCount":93},[],{"trials":282,"activeCount":93},[],{"trials":284,"activeCount":93},[],{"intervention":259,"totalTrials":89,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":288,"activeCount":93},[],{"trials":290,"activeCount":93},[],{"trials":292,"activeCount":89,"soonestReadout":39},[293],{"nctId":37,"briefTitle":38,"status":103,"phases":294,"primaryCompletion":39,"completion":254,"start":255,"enrollment":107,"conditions":295,"interventions":296},[82,83],[33],[40,258,259,260],{"trials":298,"activeCount":93},[],{"trials":300,"activeCount":93},[],{"trials":302,"activeCount":93},[],{"intervention":260,"totalTrials":89,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":306,"activeCount":93},[],{"trials":308,"activeCount":93},[],{"trials":310,"activeCount":89,"soonestReadout":39},[311],{"nctId":37,"briefTitle":38,"status":103,"phases":312,"primaryCompletion":39,"completion":254,"start":255,"enrollment":107,"conditions":313,"interventions":314},[82,83],[33],[40,258,259,260],{"trials":316,"activeCount":93},[],{"trials":318,"activeCount":93},[],{"trials":320,"activeCount":93},[],{"intervention":45,"totalTrials":89,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":324,"activeCount":93},[],{"trials":326,"activeCount":93},[],{"trials":328,"activeCount":89,"soonestReadout":44},[329],{"nctId":42,"briefTitle":43,"status":103,"phases":330,"primaryCompletion":44,"completion":44,"start":212,"enrollment":213,"conditions":331,"interventions":332},[83],[215],[45,188,217],{"trials":334,"activeCount":93},[],{"trials":336,"activeCount":93},[],{"trials":338,"activeCount":93},[],{"intervention":217,"totalTrials":89,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":342,"activeCount":93},[],{"trials":344,"activeCount":93},[],{"trials":346,"activeCount":89,"soonestReadout":44},[347],{"nctId":42,"briefTitle":43,"status":103,"phases":348,"primaryCompletion":44,"completion":44,"start":212,"enrollment":213,"conditions":349,"interventions":350},[83],[215],[45,188,217],{"trials":352,"activeCount":93},[],{"trials":354,"activeCount":93},[],{"trials":356,"activeCount":93},[],{"intervention":60,"totalTrials":89,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":360,"activeCount":93},[],{"trials":362,"activeCount":93},[],{"trials":364,"activeCount":89,"soonestReadout":59},[365],{"nctId":57,"briefTitle":58,"status":103,"phases":366,"primaryCompletion":59,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},[83],"2026-11","2025-12-05",250,[371],"Demodex Blepharitis",[60,373,374,375],"GLK-321 mid dose BID","GLK-321 high dose BID","GLK-321 high dose QD",{"trials":377,"activeCount":93},[],{"trials":379,"activeCount":93},[],{"trials":381,"activeCount":93},[],{"intervention":373,"totalTrials":89,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":385,"activeCount":93},[],{"trials":387,"activeCount":93},[],{"trials":389,"activeCount":89,"soonestReadout":59},[390],{"nctId":57,"briefTitle":58,"status":103,"phases":391,"primaryCompletion":59,"completion":367,"start":368,"enrollment":369,"conditions":392,"interventions":393},[83],[371],[60,373,374,375],{"trials":395,"activeCount":93},[],{"trials":397,"activeCount":93},[],{"trials":399,"activeCount":93},[],{"intervention":374,"totalTrials":89,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":403,"activeCount":93},[],{"trials":405,"activeCount":93},[],{"trials":407,"activeCount":89,"soonestReadout":59},[408],{"nctId":57,"briefTitle":58,"status":103,"phases":409,"primaryCompletion":59,"completion":367,"start":368,"enrollment":369,"conditions":410,"interventions":411},[83],[371],[60,373,374,375],{"trials":413,"activeCount":93},[],{"trials":415,"activeCount":93},[],{"trials":417,"activeCount":93},[],{"intervention":375,"totalTrials":89,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":421,"activeCount":93},[],{"trials":423,"activeCount":93},[],{"trials":425,"activeCount":89,"soonestReadout":59},[426],{"nctId":57,"briefTitle":58,"status":103,"phases":427,"primaryCompletion":59,"completion":367,"start":368,"enrollment":369,"conditions":428,"interventions":429},[83],[371],[60,373,374,375],{"trials":431,"activeCount":93},[],{"trials":433,"activeCount":93},[],{"trials":435,"activeCount":93},[],{"intervention":50,"totalTrials":31,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":453,"PHASE4":455,"NA":475},{"trials":439,"activeCount":93},[],{"trials":441,"activeCount":93},[],{"trials":443,"activeCount":93},[444],{"nctId":445,"briefTitle":446,"status":447,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":12,"conditions":451,"interventions":452},"NCT04615403","Study of Exchange of Travoprost Intraocular Implant","COMPLETED",[83],"2022-02-28","2020-11-19",[30],[50],{"trials":454,"activeCount":93},[],{"trials":456,"activeCount":93},[457,466],{"nctId":458,"briefTitle":459,"status":447,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":465},"NCT01444040","Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost",[85],"2019-03-28","2011-09",196,[23],[50],{"nctId":467,"briefTitle":468,"status":447,"phases":469,"primaryCompletion":470,"completion":471,"start":462,"enrollment":472,"conditions":473,"interventions":474},"NCT01443988","Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost",[85],"2017-01","2017-04",101,[23],[50],{"trials":476,"activeCount":89,"soonestReadout":49},[477],{"nctId":47,"briefTitle":48,"status":103,"phases":478,"primaryCompletion":49,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":485},[],"2026-07","2025-12-17",30,[483,484],"Open Angle Glaucoma (OAG)","Ocular Hypertension (OH)",[50],{"intervention":487,"totalTrials":89,"cells":488},"latanoprost\u002Ftimolol",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":509},{"trials":490,"activeCount":93},[],{"trials":492,"activeCount":93},[],{"trials":494,"activeCount":93},[],{"trials":496,"activeCount":93},[],{"trials":498,"activeCount":93},[499],{"nctId":500,"briefTitle":501,"status":447,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":508},"NCT00913029","Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)",[85],"2012-09","2009-05",192,[507,15,17],"Eye Diseases",[487],{"trials":510,"activeCount":93},[],{"intervention":512,"totalTrials":89,"cells":513},"Topical travoprost",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":535},{"trials":515,"activeCount":93},[],{"trials":517,"activeCount":93},[],{"trials":519,"activeCount":93},[],{"trials":521,"activeCount":93},[],{"trials":523,"activeCount":93},[524],{"nctId":525,"briefTitle":526,"status":447,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":532},"NCT02873806","Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents",[85],"2019-11-08","2013-03",53,[23],[512,533,534],"Tobramycin","Dexamethasone",{"trials":536,"activeCount":93},[],{"intervention":533,"totalTrials":89,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":547,"NA":553},{"trials":540,"activeCount":93},[],{"trials":542,"activeCount":93},[],{"trials":544,"activeCount":93},[],{"trials":546,"activeCount":93},[],{"trials":548,"activeCount":93},[549],{"nctId":525,"briefTitle":526,"status":447,"phases":550,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":551,"interventions":552},[85],[23],[512,533,534],{"trials":554,"activeCount":93},[],{"intervention":534,"totalTrials":89,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":571},{"trials":558,"activeCount":93},[],{"trials":560,"activeCount":93},[],{"trials":562,"activeCount":93},[],{"trials":564,"activeCount":93},[],{"trials":566,"activeCount":93},[567],{"nctId":525,"briefTitle":526,"status":447,"phases":568,"primaryCompletion":528,"completion":528,"start":529,"enrollment":530,"conditions":569,"interventions":570},[85],[23],[512,533,534],{"trials":572,"activeCount":93},[],{"intervention":574,"totalTrials":34,"cells":575},"riboflavin solution",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":611,"NA":613},{"trials":577,"activeCount":93},[],{"trials":579,"activeCount":93},[],{"trials":581,"activeCount":93},[],{"trials":583,"activeCount":93},[584,594,602],{"nctId":585,"briefTitle":586,"status":447,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT01643226","Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus",[84],"2015-07","2016-09","2012-07",230,[25],[574],{"nctId":595,"briefTitle":586,"status":447,"phases":596,"primaryCompletion":597,"completion":598,"start":590,"enrollment":599,"conditions":600,"interventions":601},"NCT01344187",[84],"2015-06","2016-06",236,[25],[574],{"nctId":603,"briefTitle":604,"status":199,"phases":605,"primaryCompletion":606,"completion":471,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT01972854","Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus",[84],"2016-03","2013-11",92,[25],[574],{"trials":612,"activeCount":93},[],{"trials":614,"activeCount":93},[],{"intervention":616,"totalTrials":137,"cells":617},"riboflavin ophthalmic solution",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":644,"NA":646},{"trials":619,"activeCount":93},[],{"trials":621,"activeCount":93},[],{"trials":623,"activeCount":93},[],{"trials":625,"activeCount":93},[626,635],{"nctId":627,"briefTitle":628,"status":447,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00647699","Corneal Collagen Cross-linking for Progressive Keratoconus",[84],"2011-04","2007-12",147,[33],[616],{"nctId":636,"briefTitle":637,"status":447,"phases":638,"primaryCompletion":639,"completion":639,"start":631,"enrollment":640,"conditions":641,"interventions":643},"NCT00674661","Corneal Collagen Cross-Linking for Ectasia (CXL)",[84],"2011-11",130,[642],"Ectasia",[616],{"trials":645,"activeCount":93},[],{"trials":647,"activeCount":93},[],{"intervention":649,"totalTrials":137,"cells":650},"G2-TR intraocular implant containing travoprost",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":680,"NA":682},{"trials":652,"activeCount":93},[],{"trials":654,"activeCount":93},[],{"trials":656,"activeCount":93},[],{"trials":658,"activeCount":93},[659,670],{"nctId":660,"briefTitle":661,"status":447,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT03868124","Clinical Study Comparing Two Models of a Travoprost Intraocular Implant",[84],"2022-06-10","2024-06-19","2018-09-17",560,[15,28],[649,669],"Sham surgery + active-comparator eye drops",{"nctId":671,"briefTitle":672,"status":447,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT03519386","Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%",[84],"2022-04-05","2024-04-02","2018-07-26",590,[15,28],[649,669],{"trials":681,"activeCount":93},[],{"trials":683,"activeCount":93},[],{"intervention":669,"totalTrials":137,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":702,"NA":704},{"trials":687,"activeCount":93},[],{"trials":689,"activeCount":93},[],{"trials":691,"activeCount":93},[],{"trials":693,"activeCount":93},[694,698],{"nctId":660,"briefTitle":661,"status":447,"phases":695,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":696,"interventions":697},[84],[15,28],[649,669],{"nctId":671,"briefTitle":672,"status":447,"phases":699,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":700,"interventions":701},[84],[15,28],[649,669],{"trials":703,"activeCount":93},[],{"trials":705,"activeCount":93},[],{"intervention":707,"totalTrials":89,"cells":708},"iDose TR",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":728,"NA":730},{"trials":710,"activeCount":93},[],{"trials":712,"activeCount":93},[],{"trials":714,"activeCount":93},[],{"trials":716,"activeCount":93},[717],{"nctId":718,"briefTitle":719,"status":720,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT06061718","Travoprost Intraocular Implant in Conjunction With Cataract Surgery","UNKNOWN",[84],"2024-03-18","2024-12-20","2023-09-11",60,[30,28],[707],{"trials":729,"activeCount":93},[],{"trials":731,"activeCount":93},[],{"intervention":733,"totalTrials":89,"cells":734},"riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":751,"NA":753},{"trials":736,"activeCount":93},[],{"trials":738,"activeCount":93},[],{"trials":740,"activeCount":93},[],{"trials":742,"activeCount":93},[743],{"nctId":744,"briefTitle":745,"status":746,"phases":747,"start":590,"enrollment":93,"conditions":748,"interventions":750},"NCT01643252","Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery","WITHDRAWN",[84],[749],"Corneal Ectasia",[733],{"trials":752,"activeCount":93},[],{"trials":754,"activeCount":93},[],{"intervention":756,"totalTrials":89,"cells":757},"Test Article A",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":777,"NA":779},{"trials":759,"activeCount":93},[],{"trials":761,"activeCount":93},[],{"trials":763,"activeCount":93},[],{"trials":765,"activeCount":93},[766],{"nctId":767,"briefTitle":768,"status":447,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":775},"NCT03442751","Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus",[84],"2019-11-01","2020-08-10","2018-04-06",201,[33],[756,776],"Test Article B",{"trials":778,"activeCount":93},[],{"trials":780,"activeCount":93},[],{"intervention":776,"totalTrials":89,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":795,"NA":797},{"trials":784,"activeCount":93},[],{"trials":786,"activeCount":93},[],{"trials":788,"activeCount":93},[],{"trials":790,"activeCount":93},[791],{"nctId":767,"briefTitle":768,"status":447,"phases":792,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":793,"interventions":794},[84],[33],[756,776],{"trials":796,"activeCount":93},[],{"trials":798,"activeCount":93},[],{"intervention":800,"totalTrials":137,"cells":801},"Pilocarpine Ophthalmic Topical Cream, Dose 1",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":803,"activeCount":93},[],{"trials":805,"activeCount":93},[],{"trials":807,"activeCount":93},[808,821],{"nctId":809,"briefTitle":810,"status":447,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":818},"NCT05119920","Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease",[83],"2022-07-27","2022-01-03",226,[816,817],"Dry Eye Disease","Kerato Conjunctivitis Sicca",[800,819,820],"Pilocarpine Ophthalmic Topical Cream, Dose 2","Pilocarpine Ophthalmic Topical Cream, Dose 3",{"nctId":822,"briefTitle":823,"status":447,"phases":824,"primaryCompletion":825,"completion":825,"start":813,"enrollment":826,"conditions":827,"interventions":829},"NCT05124275","Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia",[83],"2022-09-06",123,[828],"Presbyopia",[800,819,820],{"trials":831,"activeCount":93},[],{"trials":833,"activeCount":93},[],{"trials":835,"activeCount":93},[],{"intervention":819,"totalTrials":137,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":839,"activeCount":93},[],{"trials":841,"activeCount":93},[],{"trials":843,"activeCount":93},[844,848],{"nctId":809,"briefTitle":810,"status":447,"phases":845,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":846,"interventions":847},[83],[816,817],[800,819,820],{"nctId":822,"briefTitle":823,"status":447,"phases":849,"primaryCompletion":825,"completion":825,"start":813,"enrollment":826,"conditions":850,"interventions":851},[83],[828],[800,819,820],{"trials":853,"activeCount":93},[],{"trials":855,"activeCount":93},[],{"trials":857,"activeCount":93},[],{"intervention":820,"totalTrials":137,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":861,"activeCount":93},[],{"trials":863,"activeCount":93},[],{"trials":865,"activeCount":93},[866,870],{"nctId":809,"briefTitle":810,"status":447,"phases":867,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":868,"interventions":869},[83],[816,817],[800,819,820],{"nctId":822,"briefTitle":823,"status":447,"phases":871,"primaryCompletion":825,"completion":825,"start":813,"enrollment":826,"conditions":872,"interventions":873},[83],[828],[800,819,820],{"trials":875,"activeCount":93},[],{"trials":877,"activeCount":93},[],{"trials":879,"activeCount":93},[],{"intervention":881,"totalTrials":137,"cells":882},"Timolol maleate ophthalmic solution, 0.5%",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":884,"activeCount":93},[],{"trials":886,"activeCount":93},[],{"trials":888,"activeCount":93},[889,901],{"nctId":890,"briefTitle":891,"status":720,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":369,"conditions":895,"interventions":896},"NCT06152861","Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension",[83],"2024-08","2023-11-15",[30,28],[897,898,899,881,900],"Travoprost Ophthalmic Topical Cream low-dose","Travoprost Ophthalmic Topical Cream mid-dose","Travoprost Ophthalmic Topical Cream high-dose","Travoprost Ophthalmic Solution, 0.004%",{"nctId":902,"briefTitle":903,"status":447,"phases":904,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":911},"NCT02754596","Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution",[83],"2017-08-01","2020-07-21","2016-03-29",154,[910],"Glaucoma Open-angle",[912,913,914],"Travoprost Intraocular Implant, high elution","Travoprost Intraocular Implant, low elution","Timolol Maleate Ophthalmic Solution, 0.5%",{"trials":916,"activeCount":93},[],{"trials":918,"activeCount":93},[],{"trials":920,"activeCount":93},[],{"intervention":922,"totalTrials":89,"cells":923},"riboflavin ophthalmic solution, 0% dextran",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":925,"activeCount":93},[],{"trials":927,"activeCount":93},[],{"trials":929,"activeCount":93},[930],{"nctId":931,"briefTitle":932,"status":199,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":137,"conditions":937,"interventions":940},"NCT01893359","Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism",[82,83],"2015-02","2016-04","2013-08",[938,939],"Hyperopia","Hyperopic Astigmatism",[922],{"trials":942,"activeCount":93},[],{"trials":944,"activeCount":93},[],{"trials":946,"activeCount":93},[],{"intervention":897,"totalTrials":89,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":93},[],{"trials":952,"activeCount":93},[],{"trials":954,"activeCount":93},[955],{"nctId":890,"briefTitle":891,"status":720,"phases":956,"primaryCompletion":893,"completion":893,"start":894,"enrollment":369,"conditions":957,"interventions":958},[83],[30,28],[897,898,899,881,900],{"trials":960,"activeCount":93},[],{"trials":962,"activeCount":93},[],{"trials":964,"activeCount":93},[],{"intervention":898,"totalTrials":89,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":968,"activeCount":93},[],{"trials":970,"activeCount":93},[],{"trials":972,"activeCount":93},[973],{"nctId":890,"briefTitle":891,"status":720,"phases":974,"primaryCompletion":893,"completion":893,"start":894,"enrollment":369,"conditions":975,"interventions":976},[83],[30,28],[897,898,899,881,900],{"trials":978,"activeCount":93},[],{"trials":980,"activeCount":93},[],{"trials":982,"activeCount":93},[],{"intervention":899,"totalTrials":89,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":93},[],{"trials":988,"activeCount":93},[],{"trials":990,"activeCount":93},[991],{"nctId":890,"briefTitle":891,"status":720,"phases":992,"primaryCompletion":893,"completion":893,"start":894,"enrollment":369,"conditions":993,"interventions":994},[83],[30,28],[897,898,899,881,900],{"trials":996,"activeCount":93},[],{"trials":998,"activeCount":93},[],{"trials":1000,"activeCount":93},[],{"intervention":900,"totalTrials":89,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":93},[],{"trials":1006,"activeCount":93},[],{"trials":1008,"activeCount":93},[1009],{"nctId":890,"briefTitle":891,"status":720,"phases":1010,"primaryCompletion":893,"completion":893,"start":894,"enrollment":369,"conditions":1011,"interventions":1012},[83],[30,28],[897,898,899,881,900],{"trials":1014,"activeCount":93},[],{"trials":1016,"activeCount":93},[],{"trials":1018,"activeCount":93},[],{"intervention":207,"totalTrials":89,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":93},[],{"trials":1024,"activeCount":93},[],{"trials":1026,"activeCount":93},[1027],{"nctId":197,"briefTitle":198,"status":199,"phases":1028,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":1029,"interventions":1030},[83],[205],[207,208,188,209],{"trials":1032,"activeCount":93},[],{"trials":1034,"activeCount":93},[],{"trials":1036,"activeCount":93},[],{"intervention":208,"totalTrials":89,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":93},[],{"trials":1042,"activeCount":93},[],{"trials":1044,"activeCount":93},[1045],{"nctId":197,"briefTitle":198,"status":199,"phases":1046,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":1047,"interventions":1048},[83],[205],[207,208,188,209],{"trials":1050,"activeCount":93},[],{"trials":1052,"activeCount":93},[],{"trials":1054,"activeCount":93},[],{"intervention":209,"totalTrials":89,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1058,"activeCount":93},[],{"trials":1060,"activeCount":93},[],{"trials":1062,"activeCount":93},[1063],{"nctId":197,"briefTitle":198,"status":199,"phases":1064,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":1065,"interventions":1066},[83],[205],[207,208,188,209],{"trials":1068,"activeCount":93},[],{"trials":1070,"activeCount":93},[],{"trials":1072,"activeCount":93},[],{"intervention":912,"totalTrials":89,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":93},[],{"trials":1078,"activeCount":93},[],{"trials":1080,"activeCount":93},[1081],{"nctId":902,"briefTitle":903,"status":447,"phases":1082,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":1083,"interventions":1084},[83],[910],[912,913,914],{"trials":1086,"activeCount":93},[],{"trials":1088,"activeCount":93},[],{"trials":1090,"activeCount":93},[],{"intervention":913,"totalTrials":89,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1094,"activeCount":93},[],{"trials":1096,"activeCount":93},[],{"trials":1098,"activeCount":93},[1099],{"nctId":902,"briefTitle":903,"status":447,"phases":1100,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":1101,"interventions":1102},[83],[910],[912,913,914],{"trials":1104,"activeCount":93},[],{"trials":1106,"activeCount":93},[],{"trials":1108,"activeCount":93},[],{"intervention":1110,"totalTrials":89,"cells":1111},"Travoprost Intracameral Implant exchanged at Month 12",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1113,"activeCount":93},[],{"trials":1115,"activeCount":93},[],{"trials":1117,"activeCount":93},[1118],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1126},"NCT06582732","Performance of the Travoprost Intraocular Implant",[83],"2023-11-02","2021-03-10",210,[15,28],[1110,1127,1128,1129,1130,1131,1132],"Travoprost Intracameral Implant exchanged at Month 3","Travoprost Intracameral Implant exchanged at Month 6","Travoprost Intracameral Implant exchanged at Month 24","Travoprost intracameral implant exchanged at Month 21","Travoprost intracameral implant exchanged at Month 18","Travoprost intracameral implant exchanged at Month 15",{"trials":1134,"activeCount":93},[],{"trials":1136,"activeCount":93},[],{"trials":1138,"activeCount":93},[],{"intervention":1127,"totalTrials":89,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":93},[],{"trials":1144,"activeCount":93},[],{"trials":1146,"activeCount":93},[1147],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1148,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1149,"interventions":1150},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1152,"activeCount":93},[],{"trials":1154,"activeCount":93},[],{"trials":1156,"activeCount":93},[],{"intervention":1128,"totalTrials":89,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":93},[],{"trials":1162,"activeCount":93},[],{"trials":1164,"activeCount":93},[1165],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1166,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1167,"interventions":1168},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1170,"activeCount":93},[],{"trials":1172,"activeCount":93},[],{"trials":1174,"activeCount":93},[],{"intervention":1129,"totalTrials":89,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":93},[],{"trials":1180,"activeCount":93},[],{"trials":1182,"activeCount":93},[1183],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1184,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1185,"interventions":1186},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1188,"activeCount":93},[],{"trials":1190,"activeCount":93},[],{"trials":1192,"activeCount":93},[],{"intervention":1130,"totalTrials":89,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":93},[],{"trials":1198,"activeCount":93},[],{"trials":1200,"activeCount":93},[1201],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1202,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1203,"interventions":1204},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1206,"activeCount":93},[],{"trials":1208,"activeCount":93},[],{"trials":1210,"activeCount":93},[],{"intervention":1131,"totalTrials":89,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":93},[],{"trials":1216,"activeCount":93},[],{"trials":1218,"activeCount":93},[1219],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1220,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1221,"interventions":1222},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1224,"activeCount":93},[],{"trials":1226,"activeCount":93},[],{"trials":1228,"activeCount":93},[],{"intervention":1132,"totalTrials":89,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1232,"activeCount":93},[],{"trials":1234,"activeCount":93},[],{"trials":1236,"activeCount":93},[1237],{"nctId":1119,"briefTitle":1120,"status":447,"phases":1238,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":1124,"conditions":1239,"interventions":1240},[83],[15,28],[1110,1127,1128,1129,1130,1131,1132],{"trials":1242,"activeCount":93},[],{"trials":1244,"activeCount":93},[],{"trials":1246,"activeCount":93},[],{"intervention":1248,"totalTrials":89,"cells":1249},"Corneal Collagen Cross-linking",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":93},[],{"trials":1253,"activeCount":93},[],{"trials":1255,"activeCount":93},[],{"trials":1257,"activeCount":93},[],{"trials":1259,"activeCount":93},[],{"trials":1261,"activeCount":93},[1262],{"nctId":1263,"briefTitle":1264,"status":720,"phases":1265,"primaryCompletion":254,"completion":254,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1269},"NCT03319082","Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery",[],"2017-10-04",200,[749],[1248]]